Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.
Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.
Seven trials of antihyperglycemic agents from different classes have now been concluded as of May 2017. This review summarizes, compares, and contrasts the key cardiovascular (CV) and non-CV findings from these trials.
Herbst R, Bolton W, Shariff A, Green JB. Curr Diab Rep 2017;17:67. doi:10.1007/s11892-017-0898-8
This review discusses how technological advances, such as genomics, high-resolution imaging, and computational modeling, are providing new opportunities for research on the vascular complications of diabetes.
Levine et al. cautiously suggest the use of sodium-glucose co-transporter 2 inhibitors in the hospital. However, these must be used judiciously and the practitioner must be aware of euglycemic diabetic ketoacidosis and its risk factors.
Levine JA, Karam SL, Aleppo G. Curr Diab Rep 2017;17:54. doi:10.1007/s11892-017-0874-3